KSU licenses technology that could lead to developing a drug to treat the coronavirus

Amid increasing worldwide concern about a novel coronavirus, COVID-19, Kansas State University has licensed a technology that may lead to the production of an antiviral drug to treat coronaviruses and noroviruses. The university has entered into an agreement with Cocrystal Pharma Inc., a clinical stage biotechnology company that is discovering and developing novel antiviral therapeutics to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections. Read more here.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.